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Abstract
Objective: Halitosis is a widespread problem, normally attributable to specific volatile sulphur compounds (VSC)
in the breath. The aim of this study was to first relate halitosis with possible gastric infection by Helicobacter pylori
and secondly to quantify specific bacterial groups in the oral cavity flora, thus correlating them with VSC
concentrations and Proton Pump Inhibitors (PPIs) intake. Four selected lactobacilli were then assessed in the
possible reduction of halitosis in subjects with a total salivary bacterial concentration higher than 105 CFU/ml.
Methods: Specific bacterial groups, namely total bacteria, total coliforms, sulphite-reducing bacteria (SRB) and
lactobacilli, were quantified in samples of saliva from 29 subjects taking PPIs compared with 36 control subjects.
The amount of the three VSC hydrogen sulfide (H2S), methyl mercaptan (CH3SH) and dimethyl sulfide (CH3)2S in
the breath and the presence of H. pylori were determined.
Results: No significant correlation was found between H. pylori and halitosis as well as with PPIs intake. The
baseline bacterial groups quantification (log10 CFU/ml of saliva, PPI group vs. control) showed: total bacteria 8.44
vs. 4.47 (p=0.001); total coliforms 4.95 vs. 2.82 (p=0.001); sulfite-reducing bacteria 5.47 vs. 2.58 (p=0.052); total
lactobacilli 4.00 vs. 2.36 (p=0.016). After 15 days of lactobacilli supplementation, the same parameters (d15 vs
baseline) gave: total bacteria 7.92 vs. 8.44 (p=0.019); total coliforms 3.13 vs. 4.95 (p=0.001); sulfite-reducing
bacteria 4.69 vs. 5.47 (p=0.047); total lactobacilli 7.86 vs. 4.00 (p=0.048). No statistically significant differences were
noted in VSC concentrations at any time.
Conclusions: The intake of PPIs directly correlated with the overgrowth of specific bacterial groups in the oral
cavity, but there was no correlation with H. pylori or with VSC concentration. The significant reduction in all the
bacterial groups analysed after two weeks suggested the improvement of the overall oral flora in subjects chronically
treated with PPIs.
Keywords: Proton Pump Inhibitors (PPIs); Halitosis; Helicobacter
pylori; Bacterial overgrowth; Lactobacilli; Oral flora; Volatile Sulphur
Compounds (VSC).
Introduction
Halitosis, or bad breath, is a really widespread problem and
apprehension for it is valued to be the third most frequent reason for
people to seek dental care, following dental caries (tooth decay) and
periodontal disease. It is reported that about 25% of the general
population suffers from it to some extent [1]. In any case, the amount
of epidemiological research on bad breath is limited, since this topic is
still a large but underestimated taboo. A public investigation in 2005 in
The Netherlands showed that halitosis was one of the 100 biggest
human overall exasperations (TNS-NIPO).
Men and women seem to suffer in the same proportions, whereas
women seem to seek faster for professional help than men [2].
Miyazaki found that there is a clear correlation between age and oral
malodour: the older one gets, the more intense the odour will become
[3].
Of those people who have halitosis, about 90% of the time the odour
is caused by something in the mouth, commonly odours released by
bacteria present below the gumline and on the back of the tongue [4].
The remaining overall 10% is accounted for by many different
conditions, including disorders in the nose, sinuses, throat, lungs,
oesophagus, stomach or elsewhere [5]. Since halitosis is a social taboo,
psychological or social problems could often develop, such as anxiety
and depression, low self-esteem or other mood disorders.
Diagnostics of halitosis includes subjective methods (examiner’s
sense of smell) and objective methods (instrumental analysis of
specific molecules in the breath). Simple, subjective examination is
regarded as a “golden standard” in clinical practice. In case of
pathological halitosis recognizing the direct cause is crucial. After
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excluding, or after successful treatment, of all oral pathologies, in case
of remaining fetor ex ore identification and treatment of bad breath
often requires multidisciplinary approach [4].
There is an extensive list of possible causes of halitosis in the mouth
alone, however by far the most prevalent reasons reported are
halitogenic biofilm on the posterior dorsal tongue and within gingival
crevices and periodontal pockets [6]. The dorsum of the tongue, which
is irregular and has a surface of 25 cm2 is an ideal niche for oral
bacteria [7]. Since desquamating epithelial cells and food remnants are
available, putrefaction occurs. Hence, the tongue surface seems to be
an important reservoir in the recolonisation of tooth surfaces [8]. Poor
oral hygiene, dental plaque, dental caries, accumulation and
putrefaction of food remnants and unclean acrylic dentures (worn at
night or not regularly cleaned or with rough surfaces) contribute to
bad breath [9].
The putrefactive activity in the mouth may be attributable to the
proteolysis of sulphur containing amino acids in dietary and salivary
proteins by mostly anaerobic, Gram-negative bacterial species [5,10].
There are over 600 types of bacteria documented in the average
mouth. The odors are generated mainly by the hydrolysis of proteins
into individual amino acids, followed by the additional breakdown of
some of them to produce measurable foul gases. Due to this
progression, volatile sulphur compounds (VSCs) are formed. The
most important VSCs involved in halitosis are hydrogen sulfide (H2S),
methyl mercaptan (CH3SH) and dimethyl sulfide (CH3)2S. It is well
known, for example, that cysteine and methionine can produce H2S
and CH3SH, respectively [11]. VSCs have been shown to be
statistically associated with oral malodor levels, and usually decrease
following successful treatment.
Other molecules involved in this bacterial degradation process are:
diamines (indole and skatole) or polyamines (cadaverine and
putrescine). They seem to play a less important role in the expression
of bad breath. The main substrate for skatole and indole production is
tryptophan, whereas lysine and ornithine are the basis for the
putrescine/cadaverine production [5].
Most of the responsible microorganisms in halitosis are involved in
periodontitis. In this way, there is a positive correlation between bad
breath and periodontitis [12].
It could be hypothesized also a correlation between the composition
of oral cavity microbiota and possible bacterial overgrowth in the
stomach and/or upper intestine, especially in subjects presenting a
Gastro-esophageal Reflux (GERD). It is well known, in fact, that a
prolonged gastric acid suppression is associated with a larger risk of
bacterial proliferation and a higher incidence of faecal-type bacteria
[13]. Proton Pump Inhibitors (PPIs) are among the most widely used
drugs in the world and represent the most potent inhibitors of gastric
acid secretion available today.
In subjects chronically treated with acid-suppressant drugs, the risk
of Helicobacter pylori infection is increased. In turn, colonization of
the gastric mucosa by H. pylori can cause peptic ulcers. There is no
100% clear correlation found between these ulcers and halitosis
[14,15]. In vitro studies show significant VSC production by H. pylori
[16]. Moreover, it is suggested that H. pylori was detected in subjects
with periodontitis, suggesting that progression of periodontal pocket
and inflammation may favour colonization by this species and that H.
pylori infection may be indirectly associated with oral pathological
halitosis following periodontitis [17]. Kinberg et al. [18] showed that
halitosis has often been described among the symptoms related to H.
pylori infection and gastroesophageal reflux disease. When
gastrointestinal pathology was treated, most of the halitosis complaints
disappeared. Eradication treatment was found beneficial in the
treatment of children with halitosis and positive H. pylori stool
antigen test [19].
Since the oral causes of bad breath are related to microorganisms,
the therapy can consist of: (i) mechanical reduction of the intra-oral
nutrients and microorganisms; (ii) chemical reduction of
microorganisms; (iii) inverting volatile fragrant gasses into non-
volatile components or (iv) masking of the malodour [20].
Recently, several studies were performed to replace bacteria
responsible for halitosis with specific probiotics, which are live
microorganisms thought to be beneficial to the host organism and,
when administered in adequate amounts, to confer a health benefit on
the host. Lactic acid bacteria and bifidobacteria are the most common
types of microbes used as probiotics. Probiotics strengthen the
immune system to combat allergies, stress, exposure to toxic
substances and other diseases [21].
The potential application of probiotics for oral health has recently
attracted the attention of several teams of researchers. The objective is
to prevent re-establishment of non-desirable bacteria and thereby limit
the re-occurrence of oral malodour over a prolonged period. However,
only a few clinical studies have been conducted so far, and the results
to date suggest that probiotics could be useful in preventing and
treating oral infections, including dental caries, periodontal disease
and halitosis [22,23]. The oral administration of specific lactobacilli
not only seemed to improve the physiologic halitosis, but also showed
beneficial effects on bleeding from the periodontal pockets [24].
The aim of this study was to first correlate halitosis with the
presence of Helicobacter pylori in the stomach, a well-known problem
especially in subjects having an impaired intragastric acidity, and
secondly to quantify particular bacterial groups in the oral cavity flora,
thus correlating them with VSC concentrations in the breath and
Proton Pump Inhibitors (PPIs) intake. The second part of the study
was focused on quantifying the possible beneficial effects of a
formulation containing the four selected lactobacilli L. rhamnosus
LR06 (DSM 21981), L. pentosus LPS01 (DSM 21980), L. plantarum
LP01 (LMG P-21021), and L. delbrueckii subsp. delbrueckii LDD01
(DSM 22106) in the reduction of halitosis as well as in the restoration
of a healthy oral flora.
Patients and methods
Study design: A total of 65 subjects (25 males, 40 females) has
voluntarily adhered to the study, with the enrollment taking place
between March and June 2013 among the people who underwent a
gastroscopy at the Gastroenterology Unit.
Eligible subjects were selected according to the following exclusion
criteria: age younger than 18 years, ongoing pregnancy or lactation,
severe chronic degenerative diseases, severe cognitive deficits, previous
abdominal surgery, diverticulitis, immunodeficiency states, intestinal
infections, concomitant organic bowel disease, use of mouthwash or
other products for oral hygiene, treatment with antibacterial agents,
glucocorticoids or other products containing lactobacilli or
bifidobacteria in the previous two months [25].
Informed written consent was obtained from each subject. This
study was carried out in accordance with the Declaration of Helsinki
(2000) of the World Medical Association.
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Subjects were then divided into two groups. In detail, 29 subjects
were being treated with PPIs for at least 3 months (Group A), while 36
subjects were enrolled as control population (Group B).
Subjects of Group A were directed to continue therapy with their
specific PPI drug at the same dose throughout the duration of the
study.
Quantification of Volatile Sulphur Compounds (VSCs) in the
breath: The concentrations of the three VSC hydrogen sulfide (H2S),
methyl mercaptan (CH3SH) and dimethyl sulfide ((CH3)2S) in the
breath were determined by gas chromatography (OralChroma). The
OralChroma is a portable gas chromatograph offering lower cost,
higher performance and more user-friendly operations than
conventional gas chromatographs by limiting the target gases to three
types: H2S, CH3SH and (CH3)2S [26].
Detection of Helicobacter pylori infection: The presence of H.
pylori was also measured using a histopathology evaluation of antrum
biopsies. Histopathology could be regarded as accurate as the PCR of
biopsy. In detail, gastric biopsy specimens were immersed in 10%
formalin and fixed in paraffin. Sections were stained by haematoxylin
and eosin, and modified Giemsa [27,28]. Odontostomatological
evaluation: An odontostomatological visit was performed after
enrolment as well as the registration of different oro-dental health
indices. In particular, the protocol included the plaque index
(according to Dababneh) [29], the detection of the simplified index of
oral hygiene, debris and tartar (OHI-S), the gingival index (G.I.
according to Silness and Loe) [30], the bleeding index (P.B.I. according
to Saxer and Muhlemann) [31], the Winkel tongue coating index
(WTCI) [32].
Quantification of specific bacterial groups in the oral cavity: Saliva
of each subject was sampled over a 5 minute time in a sterile test tube
previously filled with 10 ml of Amies transport liquid (BD Italia,
212225). All material was stored at 4°C and delivered to the laboratory
(Biolab Research Ltd., Novara, Italy) within 24 hours after collection.
Samples were processed as soon as received and in any case within 24
hours after collection. Samples were weighed, diluted with Amies
liquid to achieve 1:10 wt/vol, homogenised and then decimally diluted
using a sterile saline. 1 ml of each appropriate dilution was plated on
specific cultural agarized media.
For total viable cells the non-selective medium LAPTg was used
[33], while the selective count of total Lactobacillus was performed on
Rogosa Acetate Agar medium (Oxoid, CM0627) [34]. Total coliforms
were selectively counted on Petrifilm CC (3M, 6410) [35], while SRB
were enumerated using tryptose-sulfite-cycloserine (TSC) (Sigma-
Aldrich, 93745) [36]. All plates seeded with lactobacilli were incubated
for 48 to 72 hours at 37°C under anaerobic conditions (GasPak
system) with Anaerocult A kits (Merck Millipore, 1138290001), while
LAPTg plates were incubated in aerobic conditions for 24 to 48 hours
at 37°C. Total coliforms were incubated in aerobic conditions at 37°C
for 24 hours, while SRB were incubated in anaerobiosis at 46°C for 24
hours.
Assessment of the efficacy of a formulation containing lactobacilli:
The subjects in the group treated with PPIs with a concentration of
total bacteria in the saliva higher than 105 cells/ml have been selected
for the intervention study with the four specific lactobacilli L.
rhamnosus LR06 (DSM 21981), L. pentosus LPS01 (DSM 21980), L.
plantarum LP01 (LMG P-21021), and L. delbrueckii subsp. delbrueckii
LDD01 (DSM 22106) delivered in the form of a chewable tablet. In
particular, the formulation contained 15 mg each of the three strains L.
rhamnosus LR06, L. pentosus LPS01, and L. plantarum LP01,
corresponding to 1.5×109 CFU/strain/dose, 5 mg of the
microorganism L. delbrueckii subsp. delbrueckii LDD01,
corresponding to 0.5×109 CFU/dose, and 1.15 grams of maltodextrin.
The total number of viable cells per chewable tablet was 5 billion
(5×109 CFU).
Subjects were directed to take one chewable tablet every day before
sleeping. The duration of such supplementation was 15 days.
At d15 saliva samples for the enumeration of the same microbial
groups as baseline were collected and analysed as previously described.
The same three VSC hydrogen sulfide (H2S), methyl mercaptan
(CH3SH) and dimethyl sulfide ((CH3)2S) were quantified in the breath
of each subject employing the OralChroma instrument, as formerly
detailed.
Lactobacilli strains in the final formulation used in this study were
kindly manufactured and provided by Probiotical Ltd., Novara, Italy.
Statistical analysis. Volatile sulphur compounds (VSC)
concentration in the saliva are expressed as mean parts per billion
(ppb) ± standard error of the mean (m ± SEM). Results of the
Helicobacter pylori detection are expressed as positive (pos), negative
(neg), not evaluated (n.e.), or uncertain. All values relating to the
concentration of total bacterial population and specific microbial
groups or genera in salivary samples are expressed as mean number of
viable cells/ml of sample ± standard deviation (m ± SD).
Paired and unpaired t-test statistical analyses were used to weigh
the results and compare them between d0 and d15 in Group A
(paired) and at d0 between the two groups (unpaired). Differences
were considered significant at p ≤ 0.05.
Results
Detection of Helicobacter pylori infection: All 65 subjects
underwent gastroscopy at baseline (d0) with the aim of detecting
possible H. pylori infection. 27 out of 29 subjects had a total bacterial
population in the mouth higher than 105 colony-forming units
(CFU)/ml and were enrolled for the 15 day supplementation with
lactobacilli. No drop out was recorded, as the preparation was very
well tolerated and accepted by each participant in Group A enrolled
for the second part of the trial.
No significant correlation was found between the presence of H.
pylori and PPIs intake (Table 1). In Group A the number of positive
results was 6 at baseline, while in the control group 9 subjects had a
positive output for what concerns this parameter. 18 patients were
negative in Group A compared with 24 subjects in the control group
(p=0.504).





Not evaluated (n.e.) 2 2
Table 1: Assessment of Helicobacter pylori infection in Group A and B
at baseline. Results are expressed as positive, negative, uncertain, or
not evaluated.
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Quantification of specific bacterial groups in the oral cavity: The
baseline bacterial groups quantification (log10 CFU/ml of saliva, PPI
group vs. control) highlighted significant differences as regards total
bacteria (8.44 vs. 4.47, p=0.001), total coliforms (4.95 vs. 2.82,
p=0.001), and total lactobacilli (4.00 vs. 2.36, p=0.016). Sulfite-
reducing bacteria (SRB), despite an almost 3 log difference between
the PPIs group and the control, showed no statistical significance (5.47
vs. 2.58, p=0.052) (Table 2a).
Parameters evaluated





Total bacteria 8.44 ± 1.15 4.47 ± 1.31 0.001
Total coliforms 4.95 ± 0.80 2.82 ± 0.96 0.001
Sulfite-reducing bacteria (SRB) 5.47 ± 1.15 2.58 ± 1.05 0.052
Lactobacilli 4.00 ± 0.93 2.36 ± 1.00 0.016
Table 2: Quantification of total bacteria, total coliforms, sulfite-
reducing bacteria (SRB), and total lactobacilli in saliva samples at d0
(both groups) (a) and d15 (Group A) (b). The data are expressed as
mean ± SD values (log10 CFU/ml of saliva) of 3 independent analysis.
p values are calculated using Student’s t-test and considered significant
if ≤ 0.05. a) comparison between the two groups at d0
After 15 days of supplementation with the four lactobacilli the
quantification of salivary bacterial groups provided the following
results: total bacteria 7.92 vs. 8.44 at time zero (p=0.019); total
coliforms 3.13 vs. 4.95 at time zero (p=0.001); sulfite-reducing bacteria
4.69 vs. 5.47 at baseline (p=0.047); total lactobacilli 7.86 vs. 4.00 at





Total bacteria 8.44 ± 1.15
**
Total coliforms 4.95 ± 0.80
Sulfite-reducing bacteria (SRB) 5.47 ± 1.15
Lactobacilli 4.00 ± 0.93
d15
Total bacteria 7.92 ± 1.40 0.019
Total coliforms 3.13 ± 0.94 0.001
Sulfite-reducing bacteria (SRB) 4.69 ± 1.10 0.047
Lactobacilli 7.86 ± 1.63 0.048
Table 2b: Comparison between time zero (d0) and d15 in Group A; **
comparison reference time (d0)
Time
Group A Group B
% %
d0
Total Lactobacillus 0.27 4.04
d15
Total Lactobacillus 64.96 /
Table 2c: Percentage of total lactobacilli at d0 in both groups and d15 in
Group A
Quantification of Volatile Sulphur Compounds (VSCs) in the
breath: No statistically significant differences were found in hydrogen
sulfide, methyl mercaptan and dimethyl sulfide concentrations,
expressed as parts per billion (ppb), in the two groups, neither at
baseline (comparison between the control population and Group A)
nor at the end of supplementation with lactobacilli compared to
baseline in subjects treated with PPIs. The threshold values of VSC
concentration normally considered as discriminants for the presence
of halitosis are as follows: 112 ppb for hydrogen sulfide, 26 ppb for
methyl mercaptan and 8 ppb for dimethyl sulfide (Table 3).
VSC evaluated
Group A Group B
p
ppb ppb
Hydrogen sulfide 7.69 ± 6.33 2.67 ± 0.73 0.444
Methyl mercaptan 289.6 ± 81.8 222.2 ± 61.6 0.549
Dimethyl sulfide 60.4 ± 10.1 62.5 ± 8.2 0.796
Table 3: Quantification of the three VSC hydrogen sulfide, methyl
mercaptan and dimethyl sulfide in the breath of subjects taking PPIs
since at least 3 months compared with control group at baseline (a)
and at the end of treatment in Group A (b). The data are expressed in
ppb as means ± Standard Error of the Mean (m ± SEM). P values are
calculated using Student’s t-test. comparison between the two groups





Hydrogen sulfide 7.69 ± 6.33 **
Methyl mercaptan 289.6 ± 81.8 **
Dimethyl sulfide 60.4 ± 10.1 **
d15
Hydrogen sulfide 4.19 ± 2.68 0.337
Methyl mercaptan 258.9 ± 85.6 0.498
Dimethyl sulfide 65.5 ± 11.2 0.804
b) comparison between time zero (d0) and d15 in Group A; **
comparison reference time (d0)
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Discussion
Halitosis is a really widespread issue, commonly attributed to the
presence of Volatile Sulphur Compounds (VSC) in the breath [4]. In
any case, the present pilot study suggests that bacterial genera in the
oral flora other than SRB, not directly enumerated in our work, may
contribute to the synthesis and secretion of VSC. In fact, SRB showed
almost a 3 log difference between subjects taking PPIs and subjects
with a normal intragastric acidity, even if the statistical comparison
gave no significance, probably due to the very high standard deviation
of the values recorded especially in Group A. However, in Group B the
concentrations of methyl mercaptan and dimethyl sulfide were only
slightly lower, if not completely overlapping, compared with
individuals treated with PPIs, and in any case consistently higher than
the respective thresholds (26 ppb and 8 ppb, respectively) in all the
conditions tested, thus suggesting an objective assessment of halitosis.
The treatment with four selected lactobacilli, given by means of oral
chewable tablets, was able to significantly decrease each bacterial
group concentration after 2 weeks, even if this had no influence on
VSC levels, as already discussed. Nonetheless, it is interesting to point
out the ability of this specific association of beneficial bacteria to help
the restoration of a plausibly healthier oral flora in subjects chronically
treated with PPIs. As it could be reasonably expected, the majority of
the oral cavity flora at the end of the supplementation period was
represented by lactobacilli (64.96%), thus demonstrating the effective
ability of such strains to integrate into the autochthonous microbiota
and to modify its composition.
There are some interesting papers demonstrating the usefulness of
lactobacilli, or other beneficial bacteria, in the amelioration or
attenuation of periodontal disease or other unfavorable conditions that
could affect the oral cavity [37-40]. A randomized controlled trial
confirmed the plaque inhibition, anti-inflammatory, and antimicrobial
effects of Lactobacillus reuteri Prodentis, actually an association of two
different microorganisms, given by means of lozenges at a daily dose
of 108 viable cells of each strain [37].
It is well known that probiotics may affect the oral ecology by
specifically preventing the adherence of other bacteria and by
modifying the protein composition of salivary pellicle. Probiotic
microorganisms could modify the protein composition of the pellicle
by two different ways, namely binding to and the degradation of
salivary proteins [41]. Most probiotics lower the pH so that other
potentially harmful microorganisms cannot form dental plaque and
calculus that causes oral inflammation.
Other mechanisms considered to be responsible for the beneficial
clinical effects of probiotics include a direct interaction with
pathogenic bacteria [42], an increase of the host immune response [43]
and a production of antimicrobial substances such as organic acids,
hydrogen peroxide and bacteriocins [44].
Our study, even if not directly focused on specific oro-dental health
indexes, demonstrated the ability of four selected lactobacilli to reduce
the concentration of coliforms and sulfite-reducing bacteria (SRB) in
the oral cavity in subjects treated with acid suppressive drugs.
In fact, it is pretty consolidated that a prolonged intake of Proton
Pump Inhibitors (PPIs) significantly causes a bacterial overgrowth in
the stomach and the duodenum [45], thus suggesting a possible role
also as concerns the composition of the oral cavity flora. Our present
results confirm that the intake of PPIs directly correlates with the
overgrowth of specific bacterial groups in the mouth, even if there is
no association with possible H. pylori gastric infection since no
differences were recorded in terms of prevalence of H. pylori detection
in the control group compared with subjects with an impaired gastric
acidity.
A previous pilot study by Del Piano et al. [45] assessed the extent of
gastric bacterial overgrowth in subjects taking PPIs either since 3 to 12
months (short-term) or since more than 12 months (long-term).
Considering the overall results collected to date on this association
of lactobacilli, it could be hypothesized their prospective usefulness in
subjects with an unbalanced oral flora composition, especially if
ascribed to the chronic intake of a PPI. In any case, future evaluations
will be needed to confirm this preliminary indications and to deeper
investigate the microbial groups and the pathways underlying the
onset and maintenance of halitosis both in subjects taking PPIs and in
control population. In fact, our findings seem to slightly reduce the
role attributable solely to SRB in the production of VSC and
consequent bad breath.
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